表紙
市場調查報告書

抑鈣素基因系胜肽 (CGRP):開發中產品分析

Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 358694
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
抑鈣素基因系胜肽 (CGRP):開發中產品分析 Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 81 Pages
簡介

本報告提供全球各國治療抑鈣素基因系胜肽 (CGRP) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • 抑鈣素基因系胜肽 (CGRP)的概要
  • 治療藥的開發
    • 臨床實驗中的產品:臨床實驗的各階段
    • 臨床實驗中的產品:各治療領域
    • 臨床實驗中的產品:不同症狀
  • 開發中產品的概要
    • 後期階段的產品
    • 初期階段的產品
  • 各企業開發中的產品
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥途徑
    • 各分子類型
  • CGRP開發治療藥的企業
    • Alder Biopharmaceuticals Inc.
    • BCN Peptides, S.A.
    • Boehringer Ingelheim GmbH
    • Eli Lilly and Company
    • BCN Peptides, S.A.
    • Teva Pharmaceutical Industries Ltd.
    • Noxxon Pharma AG
  • 藥物簡介
    • ALD-403
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • DD-04107
    • galcanezumab
    • NOXL-41
    • olcegepant
    • Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain
    • TEV-48125
  • 開發暫停的計劃
  • 開發中斷的計劃
  • 值得注意的最新趨勢·新聞稿 (全10件)
  • 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2019TDB

Summary

According to the recently published report 'Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019'; Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 9 molecules.

Calcitonin Gene Related Peptide (CGRP) - Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury. CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception.

The report 'Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019' outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Preclinical and Discovery stages are 2, 1, 4 and 2 respectively. Report covers products from therapy areas Central Nervous System and Immunology which include indications Migraine, Cluster Headache Syndrome (Cluster Headache), Dental Pain (Toothache/Tooth Pain), Fibromyalgia (Fibromyalgia Syndrome), Inflammatory Pain, Osteoarthritis Pain, Pain, Psoriasis and Traumatic Pain.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)
  • The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Calcitonin Gene Related Peptide (CGRP) - Overview
  • Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development
  • AfaSci Inc
  • Aptarion biotech AG
  • Eli Lilly and Co
  • H. Lundbeck AS
  • Living Cell Technologies Ltd
  • Nepsone ehf
  • Pharmnovo AB
  • Serometrix LLC
  • Teva Pharmaceutical Industries Ltd
  • Calcitonin Gene Related Peptide (CGRP) - Drug Profiles
  • AFAP-3 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • eptinezumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fremanezumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • galcanezumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LP-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NOXL-41 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CGRP for Pain - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit CGRP for Psoriasis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Calcitonin Gene Related Peptide (CGRP) - Dormant Products
  • Calcitonin Gene Related Peptide (CGRP) - Discontinued Products
  • Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones
  • Featured News & Press Releases
  • Oct 24, 2019: Teva to present new analyses of fremanezumab and country-specific burden of migraine at 24th World Congress of Neurology
  • Oct 02, 2019: EMGALITY (galcanezumab) now available in Canada for preventive treatment of migraine
  • Sep 05, 2019: Alder BioPharmaceuticals to Showcase Eptinezumab Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society
  • Sep 05, 2019: Lilly's migraine treatment Emgality lands in Korea
  • Sep 03, 2019: Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society
  • Aug 21, 2019: Fremanezumab data in The Lancet demonstrate clinically meaningful reduction in monthly migraine days versus Placebo for patients with difficult-to-treat migraine
  • Aug 06, 2019: Lilly reports positive data from CONQUER study of Emgality
  • Jul 15, 2019: Lilly's Emgality shows favourable profile in Phase III studies
  • Jul 11, 2019: New England Journal of Medicine publishes positive phase 3 data for Emgality (galcanezumab-gnlm) in episodic cluster headache
  • Jul 11, 2019: Alder BioPharmaceuticals presents new data on migraine-free months, migraine severity and quality of life, demonstrating eptinezumab's clinical profile for migraine prevention
  • Jul 10, 2019: Teva to present new data on AJOVY (fremanezumab-vfrm) injection at the American Headache Society's 61st Annual Scientific Meeting
  • Jul 09, 2019: Teva's Fremanezumab improves migraine-related disorders, quality of life
  • Jul 08, 2019: Alder BioPharmaceuticals to showcase 14 new data presentations demonstrating Eptinezumab's migraine prevention and quality of life impact at American Headache Society Meeting
  • Jul 04, 2019: Teva reports positive data from fremanezumab's migraine trial
  • Jun 19, 2019: Alder BioPharmaceuticals to webcast upcoming breakfast symposium with key opinion leaders
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AfaSci Inc, H2 2019
  • Pipeline by Aptarion biotech AG, H2 2019
  • Pipeline by Eli Lilly and Co, H2 2019
  • Pipeline by H. Lundbeck AS, H2 2019
  • Pipeline by Living Cell Technologies Ltd, H2 2019
  • Pipeline by Nepsone ehf, H2 2019
  • Pipeline by Pharmnovo AB, H2 2019
  • Pipeline by Serometrix LLC, H2 2019
  • Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top